Biological Effective Dose and Overall Treatment Time in the High Dose Rate Brachytherapy of Nasopharyngeal Carcinoma
International Journal of Clinical Oncology and Cancer Research
Volume 2, Issue 1, February 2017, Pages: 1-6
Received: Dec. 27, 2016; Accepted: Jan. 10, 2017; Published: Feb. 9, 2017
Views 2588      Downloads 86
Authors
Brahmacharimayum Arunkumar Sharma, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of Medical Sciences, Imphal, India
Jayshree Phurailatpam, Department of Physiology, Regional Institute of Medical Sciences, Imphal, India
Gaurav Goswami, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of Medical Sciences, Imphal, India
Thaodem Tomcha Singh, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of Medical Sciences, Imphal, India
Laishram Jaichand Singh, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of Medical Sciences, Imphal, India
Yengkhom Indibor Singh, Department of Radiotherapy, Regional Cancer Centre, Regional Institute of Medical Sciences, Imphal, India
Article Tools
Follow on us
Abstract
The aim of this study is to evaluate the decrease of biological effective dose (BED) and its correlation with local control of tumour in the treatment of nasopharyngeal carcinoma (NPC) when the overall treatment time is prolonged. A retrospective study was carried out on 39 NPC with stage II and III treated with fractionated High Dose Rate–Brachytherapy (HDR-BT)boost, following external beam radiation therapy (EBRT) treated in the period from 2009 to 2015. All patients were irradiated by HDR –Intra Luminal Radiotherapy (ILRT) following EBRT using a telecobalt unit and a technique that employed two lateral opposed fields with a dose of 66 ± 4 Gy. The total biological equivalent dose prescribed was 106.50 ± 9 Gy (range 92 - 123 Gy). The probabilities of disease recurrence within a median follow-up of 25 months (range 13 – 72 months) are expected as 0.03, 0.26, 0.58 and 0.90 (p=0.05) for the overall treatment time of 75, 150, 250 and 350 days respectively. It was observed that the local recurrence of disease increases with increased treatment time and it is significant (p=0.05) when the overall treatment time is above 100 days where BED lost becomes more than 0.10 Gy/day. The relative risk of local recurrence of stage III is about 2.59 times higher than that of stage II patients.
Keywords
HDR-ILRT, Nasopharyngeal Cancer, BED, Treatment Time
To cite this article
Brahmacharimayum Arunkumar Sharma, Jayshree Phurailatpam, Gaurav Goswami, Thaodem Tomcha Singh, Laishram Jaichand Singh, Yengkhom Indibor Singh, Biological Effective Dose and Overall Treatment Time in the High Dose Rate Brachytherapy of Nasopharyngeal Carcinoma, International Journal of Clinical Oncology and Cancer Research. Vol. 2, No. 1, 2017, pp. 1-6. doi: 10.11648/j.ijcocr.20170201.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
National cancer registry programme, North East population based cancer registries, incidence & distribution of cancer, 2nd report: 2005-2006, NCRP, Bangalore, India: Indian Council of Medical Research Sept, 2008.
[2]
Sharma AB, Singh TT, Singh KN, Gartia RK. Survey of patient dosimetry for head & neck cancer patients undergoing external radiotherapy: a study from NE hospitals of India. J cancer Res Ther 2009; 5 (4): 263-6.
[3]
Chang JT, See LC, Tang SG, Lee SP, Wang CC, Hong JH. The role of brachytherapy in early stage nasopharyngeal carcinoma. Int J RadiatOncolBiolPhys 1996; 36: 1019-24.
[4]
Hunt MA, Zelefsky MJ, Wolden S, Chui CS, LoSasso T, Rosenzweiq K, et al. Ttreatment planning and delivery of IMRT for primary nasopharynx cancer. Int J RadiatOncolBiolPhys 2001; 49: 623-32.
[5]
Marsiglia H, Haie-Meder C, Sasso G, Mamelle G, Gerbaulet A. Brachytherapy for T1-T2 floor of the mouth cancers: The Gustave-Roussy Institute experience. Int J RadiatOncolBiolPhys 2002; 52: 1257-63.
[6]
Leborgne F, Leborgne JH, Zubizarreta E, Mezzera J. Cesium-137 needle brachytherapy boost after external beam irradiation for locally advanced carcinoma of the tongue and floor of the mouth. Brachytherapy 2002; 1: 126-30.
[7]
Malde R, Agarwal JP, Gupta T, Dinshaw K. High dose rate brachytherapy boost for primary nasopharyngeal carcinoma: preliminary results of an ongoing prospective study. Bull Cancer 2005; 92 (7-8): 45-50.
[8]
Bing-Qing X, Zi-Wei T, Ya-Lan T, Zhi-Gang L, Xian-Hui L, Wei Y, et al. Forty-six cases of NPC treated with 50 Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the Sun Yat-sen University Cancer Center. Chin J Cancer 2016; 35: 37.
[9]
Nag S, Dobelbower R, Glassgow G, Gustafson G, Syed N, Thomadsen B, Williamoon JF. Inter-society standards for the performance of brachytherapy: a joint report from ABS, ACMP and ACRO. Critical Reviews in Oncology/Hematology 2003; 48: 1-17.
[10]
Shaikh T, Handorf EA, Murphy CT, Mehra R, Ridge JA, Galloway TJ. The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016; 96 (5): 967-975.
[11]
Silke T, Johanna D, Henning P, Adrian M, Alexander G, Cprdula P et al. Survival and overall treatment time after postoperative radio(chemo)therapy in patients with head and neck cancer. Head and Neck. 2016; 38 (7): 1058–1065.
[12]
Tarnawski R, Skladowski K, Swierniak A, Wygoda A, Mucha A. Repopulation of tumour cells during radiotherapy is doubled during treatment gaps. Journal of Theoretical Medicine 2000; 2: 297-305.
[13]
Sharma BA, Singh LJ, JayshreePh, Goswami G, Singh YI, Singh TT. EQD2 and Overall Treatment Time in the HDR Brachytherapy of the Advanced NPC. J Nasopharyngeal Carcinoma, 2016, 3 (5), e33. doi: 10.15383/jnpc.33.
[14]
Maciejewski B, Preuss-Bayer G,Trott KR. The influence of three numbers of fractions and of overall time on local control and late complications rate in squamous cell carcinoma of the larynx. Int J RadiatOncolBiolPhys 1983; 9: 321-8.
[15]
Horiot JC, Bontemps P, Van den Bogaert W, Le Fur R, van den Weijnqaert D, Bolla M, et al. Accelerated fractionation compared to conventional fractionation improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. RadiotherOncol 1997; 44 (2): 111-21.
[16]
Dische S, Saunders M, Barret A, Harvey A, Gibson D, Parmar M. A randomised multicentre trial of CHART vs conventional radiotherapy in head and neck cancer. RadiotherOncol 1997; 44 (2): 123-36.
[17]
Dale RG. The application of linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-28.
[18]
Ledorgne F, Fowler JF, Leborgne JF, Zubizerreta E, Chappell R. Biologically effective doses in medium dose rate brachytherapy of cancer of the cervix. RadiatOncolInvestig 1997; 5: 289-99.
[19]
Stewart AJ, Jones B. Radiobiologic concepts for brachytherapy. In: Brachytherapy applications and techniques. Devlin PM(ed). Lippincott Williams &Wilkins, Philadelphia 2007.
[20]
Dimopoulos JCA. Dose volume histogram parameters and local tumour control in MRI guided cervical cancer brachytherapy. Int J RadiatOncolBiolPhys 2009; 75: 56-63.
[21]
Sharma AB, Singh TT, Singh JL, Singh IY, Devi SY. Biological effective doses in the intracavitary high dose rate brachytherapy of cervical cancer. Journal of Contemporary Brachytherapy 2011; 3 (4): 188-92.
[22]
Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue response. Int J RadiatOncolBiolPhys1982; 8: 1981-97.
[23]
Thames HD, Withers HR, Peters LJ, Fletcher GH. Changes in early and late radiation responses with altered dose fractionation: implications for dose survival relationships. Int J RadiatOncolBiolPhys1982; 8: 219-26.
[24]
Sood B, Garg M, Avadhani J, Gorla G, Malhotra H, Guha C et al. Predictive value of linear-quadratic model in the treatment of cervical cancer using HDR brachytherapy. Int J RadiatOncolBiolPhys2002; 54: 1377-87.
[25]
Dala RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985; 58: 515-28.
[26]
Fowler J. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 1989; 62: 679-94.
[27]
Potter R, Haie-Meder C, Van Limbergen E, Barillat I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters aspects of 3D image-based anatomy, radiation physics, radiobiology. RadiotherOncol 2006; 78: 67-77.
[28]
Passi K, Kehwar TS, Vashistha R, Singh B, Jain V, Gupta ST. High dose rate brachytherapy with EBRT in the treatment of carcinoma of cervix: dosimetic and radiobiologic analysis. Journal of Radiotherapy in practice 2009; 8: 215-27.
[29]
Stanton PD, Cooke TG, Foster G, Smith D, Going JJ. Cell Kinetics in vivo of human breast cancer. Br J Surg 1996; 83 (1): 98-102.
[30]
Keisch M, Vicini F, Kuske RR, Hebert M, White j, Quiet C et al. Initial clinical experience with the MammoSite breast brachytherapy application in woman with early-stage breast cancer treated with conserving therapy. Int J RadiatOncolBiolPhys 2003; 55 (2): 289-93.
[31]
Kim Y,Werts ED, Trombetta MG, Miften M. Evaluation of the interfractional biological effective dose(BED) variation in MammoSite HDR brachytherapy. Journal of applied clinical medical physics 2010; 11 (3): 124-34.
[32]
Michael C Joiner. A simple α/β – independent method to derive fully isoeffective schedules following changes in dose per fraction. Int J RadiatOncolBiolPhys2004; 58: 871-5.
[33]
Levendaq PC, Nijdam WM, Van Aqthoven M, Uyl-de Groot CA. Chemotherapy and HDR brachytherapy in the management of advanced cancers of the nasopharynx: clinical impact of high technology – is it worth the cost? Brachytherapy 2002; 1: 11-20.
[34]
Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. ClinOncol (R CollRadiol) 2001; 13: 71-81.
[35]
Jones B, Dale RG. The reduction of tumour control with increasing overall time: Mathematical considerations. Br J Radiol. 1996; 69: 830-8.
[36]
Tucker SL. Pitfalls in estimating the influence of overall treatment time on local tumour control. ActaOncol. 1999; 38: 171-178.
[37]
Mandal A, Anupam KA, Lalit MA. Clinical significance of cumulative BED and overall treatment time in the treatment of carcinoma cervix. J Med Phys. 2007; 32 (2): 68-72.
[38]
Li P-J, Jin T, Luo D-H, Shen T, Mai DM, Hu WH et al. Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. PLoS ONE. 2015; 10(10):e0141332. doi:10.1371/journal.pone.0141332.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186